Loading…
SNGX
Soligenix Inc
NASDAQ· Healthcare· Biotechnology· CUSIP 834223604
$0.38-0.84%Price as of Aug 29, 18:41 UTC · updated once a day, after the close
Key metrics
- Market cap
- $8.2M
- P/E
- —
- Forward P/E
- —
- P/B
- 1.2x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.72
- ROE
- -241.65%
- Profit margin
- 0.00%
- Revenue growth
- —
- Beta
- 1.92
- 52-week high
- $3.22
- 52-week low
- $0.28
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.8% over 5Y.
today you would have $1.51▼ -99.8%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $1.34 | $2.70 | $12.16 | $108.00 | |
| P/S | — | — | — | — | 78.5x |
| P/B | 2.6x | 2.6x | 1.6x | 3.1x | — |
| EPS | -$2.14 | -$4.98 | -$12.66 | -$76.96 | |
| Profit margin | — | — |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BMGLBasel Medical Group Ltd | $5.24 | — | 1.7x | — | -147.37% | $8.2M |
| LUCYInnovative Eyewear Inc | $0.95 | — | 0.9x | — | -84.58% | $8.18M |
| CNSPCNS Pharmaceuticals, Inc. | $5.52 | — | 0.4x | — | -106.62% | $8.07M |
| CUPRCuprina Holdings (Cayman) LTD | $3.01 |
About the company
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator (IDR) technology that is in Phase 3 clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX945, an IDR technology that is in Phase 2a study to treat aphthous ulcers in Behçet's disease; and SGX302, an IDR technology, which is in Phase 2a study for the treatment of mild-to-moderate psoriasis. Its Public Health Solutions segment engages in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a, 1b, and 1c clinical trials; SGX943, a therapeutic candidate in preclinical studies for the treatment of antibiotic-resistant and emerging infectious diseases; ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines; CiVax, a vaccine candidate for the prevention of COVID-19; and vaccine programs that target filoviruses, such as Marburg and Ebola. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in September 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
- 13
- Princeton, United States
Company description provided by Yahoo Finance.